Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

E 1 Yahyi He
B 2 Yan Wang
E 3 Theresa Boyle
B 1 Shengxiang Ren
C 3 Dan Chan
F 3 Chris Rivard
F 2 Xuefei Li
E 2 Jiayu Li
AG 1 Caicun Zhou
F 3 Fred R. Hirsch

Corresponding Author: Caicun Zhou, e-mail: caicunzhoudr@163.com

Source of support: This study was supported in part by a grant from the Young Scientist Program of Shanghai National Health and Family Planning Commission and a grant from the Chronic Disease Comprehensive Prevention and Control Project of the Shanghai Shenhkang Hospital Development Center (No. SHDC12012313)

Background: Hepatocyte growth factor (HGF)-mediated mesenchymal-to-epithelial transition factor (MET) gene amplification is a common mechanism for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). MET gene amplification has also been associated with hepatic metastases in patients with lung cancer. The aim of this study was to investigate whether hepatic metastases are associated with decreased efficacy of erlotinib in patients with adenocarcinoma.

Material/Methods: A cohort of 329 patients with stage IV lung adenocarcinoma, known EGFR mutation status, and who received treatment with erlotinib in the 2nd or 3rd line setting were enrolled into this study over a period of 4 years between January 2011 and January 2015. The cohort was stratified based on the presence or absence of hepatic metastases and the efficacy of erlotinib was defined based on disease control rate (DCR) and progression-free survival (PFS).

Results: Hepatic metastases were present in 220 of the 329 enrolled lung adenocarcinoma patients. EGFR-activating mutations (exon 19 deletion or an exon 21 L858R mutation) were identified in 113 (34.3%) patients. The DCR was significantly lower in the hepatic metastases group than in patients without hepatic metastases (39.5% vs. 51.4%, P=0.045). In patients with hepatic metastases, median PFS was 2.3 months in the EGFR mutation-positive group versus 1.4 months in the EGFR mutation-negative group (95% CI 1.3–3.3 vs. 1.3–1.5; P=0.055). Of note, erlotinib therapy in patients with hepatic metastases was complicated by elevated alanine transaminase (ALT) levels.

Conclusions: Hepatic metastasis in patients with lung adenocarcinoma predicts poor response to erlotinib as a 2nd/3rd line therapy. Combination therapy, for example with MET-TKI, may be a good choice for patients with liver metastases with poor prognosis.

MeSH Keywords: Adenocarcinoma • Genes, erbB-1 • Neoplasm Metastasis

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/896607
Background

Lung cancer has high mortality worldwide [1–3]. Unfortunately, most patients with non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage [2]. Platinum-based doublet chemotherapy is the standard 1st line therapy for advanced NSCLC [4,5]. Single-agent chemotherapy is used in the treatment of advanced NSCLC in 2nd line therapy, while the response rate (RR) is low and all of these agents have different toxicity profiles [6,7]. Guidelines by the IASLC, CAP, and AMP recommend epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement genetic testing of NSCLCs with an adenocarcinoma histological type or even a component of adenocarcinoma as the standard of care. Tyrosine kinase inhibitor (TKI) therapy is indicated as the standard of care for patients with adenocarcinomas that harbor EGFR mutations. EGFR-TKIs, such as gefitinib, erlotinib, icotinib, and afatinib, have been widely used not only in 1st line therapy, but also in maintenance and 2nd/3rd line therapy in advanced NSCLC [8–11].

However, some patients with EGFR mutation do not respond well to EGFR-TKIs. Additionally, nearly all the patients initially responding to EGFR-TKIs inevitably develop acquired resistance. Hepatocyte growth factor (HGF)-mediated mesenchymal-to-epithelial transition factor (MET) amplification through activating ERBB3/Pi3K/AKT signaling is an important mechanism for acquired resistance to EGFR-TKI, and also plays an important role in the process of hepatic metastases. The incidence of hepatic metastases in patients with lung cancer is high, with rates as high as 37–51% [12–15]. Therefore, we hypothesized that hepatic metastasis predicts poor efficacy of EGFR-TKI [16,17].

In this study, we compared the efficacy of erlotinib in the 2nd/3rd line setting in 329 pulmonary adenocarcinoma patients stratified by the presence or absence of hepatic metastasis.

Material and Methods

Patients

From January 2011 to January 2015, 220 lung adenocarcinoma patients with hepatic metastases were enrolled into the study, and 109 stage IV lung adenocarcinoma patients without hepatic metastases were recruited continuously from January 2011. Eligible patients had confirmed stage IV lung adenocarcinoma (Union for International Cancer Control classification version 7) with a confirmed activating mutation of EGFR (exon 19 deletion or an exon 21 L858R mutation). All patients received 2nd/3rd line chemotherapy treatment and had platinum-based doublet chemotherapy as 1st line therapy. They also had measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), an Eastern Cooperative Oncology Group performance status (PS) of 0–2, age ≥18, and adequate hematological, biochemical, and organ function. Patients with unstable systemic disease or uncontrolled brain metastases were excluded. This research was approved by the Ethics Committee of Shanghai Pulmonary Hospital, Tongji University, and informed consent was obtained from all of the patients before enrollment.

Treatment

We performed history-taking, physical examination, hematologic and biochemical testing, and chest and abdomen computed tomographic scans before erlotinib treatment. Assessments of toxic effects and quality of life were obtained. Patients received erlotinib 150 mg daily. Assessment of toxicity was done according to National Cancer Institute Common Toxicity Criteria version 4.0. Patients were evaluated every 3 weeks, and hematology and blood chemistry analyses were done. Tumor size was assessed every 6 weeks [18–20].

DNA extraction and EGFR mutation analysis

All EGFR mutational analyses were performed using the Amplification Refractory Mutation System (ARMS) in Tongji University Medical School Cancer Institute (Shanghai, China). The details were described in our previous articles [21,22].

Statistical analysis

The chi-square test was used to analyze the association between hepatic metastases and clinical data and disease control rate (DCR). For the survival analysis, patients were censored at the last date at which they were known to be alive. All time-to-event outcomes, such as progression-free survival (PFS), were estimated using the Kaplan-Meier method and compared across groups with the log-rank test or the Cox proportional hazards model. The SPSS statistical package for Windows version 13.0 was used. All P values were 2-sided, and statistical significance was defined as p<0.05.

Results

Patient characteristics

We enrolled 329 stage IV lung adenocarcinoma patients with known EGFR mutation status. Table 1 shows the clinical characteristics of all the patients. Hepatic metastases was more common in patients younger than 65 years old (p=0.028), and the PS of these patients was significantly higher (p<0.001) (Table 1).
Table 1. Characteristics of all cases.

| Items                        | Total          | Hepatic metastases | EGFR mutation | P  | Negative | Positive | P     |
|------------------------------|----------------|--------------------|---------------|----|----------|----------|-------|
|                              | No            | Yes                | P             |    |          |          |       |
| Sex, n (%)                   |                |                    |               |    |          |          |       |
| Male                         | 168 (51.1%)    | 53 (48.6%)         | 115 (51.4%)   | 0.559 | 127 (58.8%) | 41 (36.3%) | <0.001 |
| Female                       | 161 (48.9%)    | 56 (52.3%)         | 105 (47.7%)   |     | 89 (41.2%) | 72 (63.7%) |       |
| Age, mean                    | 57             | 60                 | 55            |     | 56       | 58       |       |
| <65; n (%)                   | 251 (76.3%)    | 75 (68.8%)         | 176 (80.0%)   | 0.028 | 171 (79.2%) | 80 (70.8%) | 0.102  |
| ≥65; n (%)                   | 78 (23.7%)     | 34 (31.2%)         | 44 (20.0%)    |     | 45 (20.8%) | 33 (29.2%) |       |
| Smoking, n (%)               |                |                    |               |    |          |          |       |
| Smoker                       | 155 (47.1%)    | 45 (41.3%)         | 110 (50.0%)   | 0.159 | 121 (56.0%) | 34 (30.1%) | <0.001 |
| Non-smoker                   | 174 (52.9%)    | 64 (58.7%)         | 110 (50.0%)   |     | 95 (44.0%) | 79 (69.9%) |       |
| Performance status (ECOG), n (%) |            |                    |               |    |          |          |       |
| 0–1                          | 271 (82.3%)    | 105 (96.3%)        | 166 (75.5%)   | <0.001 | 173 (80.1%) | 98 (86.7%) | 0.170  |
| 2                            | 58 (17.6%)     | 4 (3.7%)           | 54 (24.5%)    |     | 43 (19.9%) | 15 (13.3%) |       |
| T stage, n (%)               |                |                    |               |    |          |          |       |
| 1–2                          | 80 (24.3%)     | 31 (28.4%)         | 49 (22.3%)    | 0.223 | 48 (22.2%) | 32 (28.3%) | 0.226  |
| 3–4                          | 249 (75.7%)    | 78 (71.6%)         | 171 (77.7%)   |     | 168 (77.8%) | 81 (71.7%) |       |
| N stage, n (%)               |                |                    |               |    |          |          |       |
| 0–1                          | 51 (15.5%)     | 18 (16.5%)         | 33 (15.0%)    | 0.747 | 30 (13.9%) | 21 (18.6%) | 0.266  |
| 2–3                          | 278 (84.5%)    | 91 (83.5%)         | 187 (85.0%)   |     | 186 (86.1%) | 92 (81.4%) |       |
| Metastasis sites             |                |                    |               |    |          |          |       |
| Brain                        | 101 (30.7%)    | 70 (69.3%)         | 31 (30.7%)    |     | 59 (58.4%) | 42 (41.6%) |       |
| Bone                         | 61 (18.5%)     | 42 (68.9%)         | 19 (31.1%)    |     | 41 (67.2%) | 20 (32.8%) |       |
| Pleura                       | 89 (27.1%)     | 67 (75.3%)         | 22 (24.7%)    |     | 55 (61.8%) | 34 (38.2%) |       |
| Liver                        | 220 (66.9%)    | 0 (0.0%)           | 220 (100%)    |     | 153 (69.5%) | 67 (30.5%) |       |
| Lung                         | 92 (28.0%)     | 62 (67.4%)         | 30 (32.6%)    |     | 65 (70.7%) | 27 (29.3%) |       |
| Other sites                  | 51 (15.5%)     | 29 (56.9%)         | 22 (43.1%)    |     | 27 (52.9%) | 24 (47.1%) |       |
| Number of hepatic metastases, n (%) |            |                    |               |    |          |          |       |
| ≤3                           | 141 (64.1%)    | 93 (61.2%)         | 48 (70.6%)    | 0.224 |
| >3                           | 79 (35.9%)     | 59 (38.8%)         | 20 (29.4%)    |     |           |          |       |
| EGFR mutation, n (%)         |                |                    |               |    |          |          |       |
| Negative                     | 216 (65.7%)    | 64 (58.7%)         | 152 (69.1%)   | 0.066 |
| Positive                     | 113 (34.3%)    | 45 (41.3%)         | 68 (30.9%)    |     |           |          |       |
| Exon 19 deletion             | 69 (61.1%)     |                   |               |     |           |          |       |
| Exon 21 mutation             | 44 (38.9%)     |                   |               |     |           |          |       |
Table 2. Therapeutic effect in patients without hepatic metastases and with hepatic metastases.

|                           | Without hepatic metastases | With hepatic metastases | P   |
|---------------------------|-----------------------------|-------------------------|-----|
| **Total, n (%)**          |                             |                         |     |
| SD+PR+CR                  | 56                          | 87                      | 0.045 |
| PD                        | 53                          | 133                     |     |
| **Sex, n (%)**            |                             |                         |     |
| Male                      |                             |                         |     |
| SD+PR+CR                  | 25                          | 25                      | <0.001 |
| PD                        | 25                          | 90                      |     |
| Female                    |                             |                         |     |
| SD+PR+CR                  | 28                          | 62                      | 0.318 |
| PD                        | 28                          | 43                      |     |
| **Age, n (%)**            |                             |                         |     |
| <65                       |                             |                         |     |
| SD+PR+CR                  | 35                          | 63                      | 0.121 |
| PD                        | 40                          | 113                     |     |
| ≥65                       |                             |                         |     |
| SD+PR+CR                  | 21                          | 24                      | 0.645 |
| PD                        | 13                          | 20                      |     |
| **Smoking, n (%)**        |                             |                         |     |
| Smoker                    |                             |                         |     |
| SD+PR+CR                  | 22                          | 26                      | 0.004 |
| PD                        | 23                          | 84                      |     |
| Non-smoker                |                             |                         |     |
| SD+PR+CR                  | 34                          | 61                      | 0.875 |
| PD                        | 30                          | 49                      |     |
| **Performance status (ECOG), n (%)** | | |       |
| 0–1                       |                             |                         |     |
| SD+PR+CR                  | 53                          | 65                      | 0.079 |
| PD                        | 12                          | 101                     |     |
| 2                         |                             |                         |     |
| SD+PR+CR                  | 3                           | 22                      | 0.305 |
| PD                        | 1                           | 32                      |     |
| **T stage, n (%)**        |                             |                         |     |
| 1–2                       |                             |                         |     |
| SD+PR+CR                  | 20                          | 20                      | 0.066 |
| PD                        | 11                          | 29                      |     |
| 3–4                       |                             |                         |     |
| SD+PR+CR                  | 67                          | 62                      | 0.333 |
| PD                        | 42                          | 104                     |     |
| **N stage, n (%)**        |                             |                         |     |
| 0–1                       |                             |                         |     |
| SD+PR+CR                  | 10                          | 117                     | 1.000 |
| PD                        | 17                          | 51                      |     |
| 2–3                       |                             |                         |     |
| SD+PR+CR                  | 46                          | 70                      | 0.039 |
| PD                        | 45                          | 117                     |     |
| **Number of hepatic metastases, n (%)** | | |       |
| ≤3                        |                             |                         |     |
| SD+PR+CR                  | 66                          | 66                      | 0.004 |
| PD                        | 75                          | 75                      |     |
| >3                        |                             |                         |     |
| SD+PR+CR                  | 21                          | 21                      |     |
| PD                        | 58                          | 58                      |     |
| **EGFR mutation, n (%)**  |                             |                         |     |
| Negative                  |                             |                         |     |
| SD+PR+CR                  | 17                          | 52                      | 0.338 |
| PD                        | 47                          | 100                     |     |
| Positive                  |                             |                         |     |
| SD+PR+CR                  | 31                          | 35                      | <0.001 |
| PD                        | 6                           | 33                      |     |
Therapeutic effect

In the hepatic metastases group, the disease control rate was 39.5%, while in patients without hepatic metastases the disease control rate was 60.5% (P=0.045) (Table 2). In males (p<0.001), smokers (p=0.004), N2-3 (p=0.039), number of hepatic metastases >3 (p=0.004), and EGFR-positive (p<0.001) patients, the DCR rate was higher in patients without hepatic metastases than in patients with hepatic metastases.

Survival analysis

Median PFS in EGFR mutation-positive patients was 4.4 months and it was 1.4 months in EGFR mutation-negative patients (95% CI 2.799–6.001 vs. 1.329–1.471; P<0.001).

In patients with hepatic metastases, median PFS was 2.3 months in the EGFR mutation-positive group and 1.4 months in the EGFR mutation-negative (95% CI 1.314–3.286 vs. 1.325–1.475; P=0.055) (Figure 1).

In EGFR mutation-positive patients, median progression-free survival (PFS) was significantly longer in patients without hepatic metastases than in those with hepatic metastases (9.1 [95% CI 8.023–10.177] vs. 2.3 [1.314–3.286] months; P<0.001) (Figure 2).

Survival analysis in the whole population was performed (Table 3). The progression-free survival benefit seemed to be consistent across all clinical subgroups irrespective of sex, age, performance status, smoking status, T stage, N stage, number of hepatic metastases, or hepatic metastases status, suggesting that smoking status, EGFR mutations, and hepatic metastases are the most important factor in the PFS benefit in the whole population survival analysis.

Treatment-related adverse effects

The most frequent drug-related adverse effects were mild-to-moderate skin toxicity (56.1%) and diarrhea (55.3%) (Table 4). Liver toxicity was observed in more than 20% of patients without hepatic metastases. Dose reduction to 100 mg/d was necessary in 21 patients with hepatic metastases, due to increased alanine transaminase (ALT).

Discussion

The aim of our study was to investigate efficacy of erlotinib as 2nd/3rd line treatment in Chinese lung adenocarcinoma patients with hepatic metastases. We found that hepatic metastasis is a poor predictive marker for erlotinib in 2nd/3rd line treatment in patients with lung adenocarcinoma.

In advanced NSCLC, docetaxel or pemetrexed as the 2nd line chemotherapy can prolong survival after 1st line chemotherapy for NSCLC [6,7]. A study showed that in patients treated with docetaxel as 3rd line chemotherapy, survival was identical to that of patients treated with supportive care, but time to progression was longer for docetaxel patients than for best supportive care patients [6]. Erlotinib and gefitinib have been widely studied [23–37]. In phase II clinical trials of gefitinib [35,36], 10–20% of patients who received gefitinib after the 1st line therapy responded to gefitinib, and in a phase II
clinical trial of erlotinib in previously treated NSCLC patients, the response rate was 12.3% [37]. These response rates are higher than with chemotherapy [6,7]. Clinical trials also demonstrated that erlotinib can prolong survival in previously treated NSCLC patients [11].

In our study, hepatic metastases were more common in the patients younger than 65 years old, and the PS of these patients were significantly higher. The DCR was 60.5% in patients with out hepatic metastases, which is similar to results of a previous study [11]. However, the DCR and PFS in patients with hepatic metastases were lower than in patients without hepatic metastases. In males and smokers, N2–3, number of hepatic metastases >3, number of EGFR-positive patients, and DCR rate were significant higher in patients without hepatic metastases than in patients with hepatic metastases. In patients with hepatic metastases, PFS was not significantly different between the EGFR mutation-positive group and the EGFR mutation-negative group.

Lung cancer with EGFR-activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib.

**Table 3. Survival analysis in the whole population.**

|                        | HR    | P       | 95%CI          |
|------------------------|-------|---------|----------------|
| Sex (Male vs. Female)  | 1.087 | 0.703   | 0.709–1.665    |
| Age (≤65 vs. ≥65)      | 0.799 | 0.112   | 0.602–1.061    |
| ECOG PS (0–1 vs. 2–3)  | 0.802 | 0.182   | 0.581–1.109    |
| Smoking status (Yes vs. No) | 0.605 | 0.029   | 0.385–0.949    |
| T stage (1–2 vs. 3–4)  | 1.331 | 0.065   | 0.983–1.802    |
| N stage (0–1 vs. 2–3)  | 0.807 | 0.220   | 0.572–1.137    |
| Number of hepatic metastases (≤3 vs. >3) | 0.860 | 0.359 | 0.622–1.188 |
| EGFR mutation (No vs. Yes) | 0.420 | <0.001 | 0.311–0.566 |
| Hepatic metastases (No vs. Yes) | 1.830 | <0.001 | 1.331–2.515 |

**Table 4. Treatment-related adverse effects.**

| Toxicity, n (%) | Without hepatic metastases | With hepatic metastases | Total |
|-----------------|----------------------------|-------------------------|-------|
|                 | Any grade | Grade 3 or 4 | Any grade | Grade 3 or 4 | Any grade | Grade 3 or 4 |
| Neutropenia     | 3 (2.8%)  | 0 (0.0%)     | 17 (7.7%) | 0 (0.0%)     | 20 (6.1%) | 0 (0.0%)     |
| Thrombocytopenia| 2 (1.8%)  | 0 (0.0%)     | 15 (6.8%) | 0 (0.0%)     | 17 (5.2%) | 0 (0.0%)     |
| Anemia          | 6 (5.5%)  | 0 (0.0%)     | 12 (5.5%) | 5 (2.3%)     | 18 (5.5%) | 5 (1.5%)     |
| Infection       | 4 (3.7%)  | 0 (0.0%)     | 9 (4.1%)  | 0 (0.0%)     | 13 (4.0%) | 0 (0.0%)     |
| Skin rash       | 62 (56.9%)| 2 (1.8%)     | 120 (54.5%)| 4 (1.8%)    | 182 (56.1%)| 6 (1.8%)     |
| Diarrhea        | 32 (28.4%)| 0 (0.0%)     | 62 (28.2%)| 0 (0.0%)     | 94 (55.3%)| 0 (0.0%)     |
| Stomatitis      | 21 (29.4%)| 0 (0.0%)     | 33 (15.0%)| 0 (0.0%)     | 54 (17.7%)| 0 (0.0%)     |
| Paronychia      | 17 (15.6%)| 0 (0.0%)     | 35 (15.0%)| 0 (0.0%)     | 52 (16.4%)| 0 (0.0%)     |
| Vomiting or nausea | 9 (8.3%) | 0 (0.0%) | 23 (10.5%) | 0 (0.0%) | 32 (9.7%) | 0 (0.0%) |
| Increased ALT   | 25 (22.9%)| 0 (0.0%)     | 77 (35.0%)| 21 (9.5%)    | 102 (31.0%)| 21 (6.4%)    |
| Fatigue         | 15 (13.8%)| 0 (0.0%)     | 37 (16.8%)| 2 (1.0%)     | 52 (15.8%)| 2 (0.06%)    |
However, many patients with EGFR-activating mutations show intrinsic resistance. In our research, DCR and PFS were lower in patients with hepatic metastases, perhaps because HGF, a ligand of MET oncoprotein, induces EGFR TKI resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the phosphatidylinositol 3-kinase/Akt signaling pathway via phosphorylation of MET, but not EGFR or ErbB3 [14]. MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers, and causes resistance to EGFR kinase inhibitors. MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling [15]. We should also consider the possibility that the actual status of EGFR genes in hepatic metastases could be different from the status of the tumor sample analyzed. The samples used for EGFR gene analysis in this study were derived from lung tumors before initiation of chemotherapy, not from liver tumors, and all the patients had received 1 or 2 prior chemotherapy regimens. Previous research suggests that the EGFR mutation status changes after chemotherapy [39]. All the above-mentioned factors may influence the efficacy of erlotinib and may cause poor curative effect of erlotinib in the liver.

Erlotinib was well tolerated in our study. The most common toxicities are rash and diarrhea in patients without hepatic metastases. Patient response was primarily correlated with the grade of rash, consistent with results of several other trials [11]. Patients who had hepatic metastases had much higher ALT levels after taking EGFR-TKIs. Hepatic function should receive more attention in patients with hepatic metastases.

Our study has some limitations which should be taken into consideration. Firstly, this was a retrospective study. Secondly, the patients in our study came from a single center.

Conclusions

We found that hepatic metastasis is a poor predictive marker for erlotinib as 2nd/3rd line treatment in patients with lung adenocarcinoma. Combination therapy, for example with MET-TKI, may be a good choice for patients with liver metastases with poor prognosis. Further research is needed to explore the overall survival between patients with hepatic metastases and patients without hepatic metastases.

Conflict of interest statement

There are no conflicts of interest.

References:

1. Ferlay J, Shin HR, Bray F et al: Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer, 2010; 127: 2839–917
2. Jemal A, Bray F, Center MM et al: Global cancer statistics. Cancer J Clin, 2011; 61: 69–90
3. Jemal A, Murray T, Ward E et al: Cancer statistics 2005. Cancer J Clin, 2005; 55: 10–30
4. Pfister DG, Johnson DH, Azozil CG et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol, 2004; 22: 330–53
5. D’Addario G, Pittile M, Leighl NB et al: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol, 2005; 23: 2926–36
6. Shepherd FA, D’Addario G, Le Chevalier T et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000; 18: 2095–103
7. Rossella FV, DeGore R, Kerr RN et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 2000; 18: 2354–62 [Erratum: J Clin Oncol, 2004; 22: 209].
8. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res, 2006;12: 6049–55
9. Zhou C, Wu YL, Chen G et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011; 12: 735–42
10. Lee JK, Kim TM, Koh Y et al: Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer, 2012; 77: 460–63
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005; 353: 1231–32
12. Stenbygaard LE, Sorensen JB, Larsen H, Dombrowsky P: Metastatic pattern in non-resectable non-small cell lung cancer. Acta Oncol, 1999; 38: 99–108
13. Tan F, Aydinler A, Topuz E et al: Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol, 1999; 38: 1011–15
14. Yano S, Wang W, Li Q et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epithelial growth factor receptor activating mutations. Cancer Res, 2008; 68: 9479–87
15. Turke AB, Zejnullahu K, Wu YL et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010; 17: 77–88
16. Martelli O, Coppola L, De Quarto AL et al: Fulminating hepatic failure caused by diffuse intrasinusoidal metastatic liver disease: a case report. Tumori, 2000; 86: 424–27
17. Ibara N, Yashiro N, Kinoshiba T et al: Diffuse intrasinusoidal liver metastasis of small cell lung cancer causing fulminant hepatic failure: CT findings – a case report. Radiat Med, 2001; 19: 275–77
18. Therasse P, Arbuck SG, Eisenhauer EA et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000; 92: 205–16
19. Lilenbaum RC, Herndon JE II, List MA et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (9730). J Clin Oncol, 2005; 23: 190–96
20. Georgoulis V, Ardavanis A, Agelidou A et al: Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J Clin Oncol, 2004; 22: 2602–9
21. Ren S, Kang P, Zheng L et al: Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys, 2012; 64: 155–60
22. He Y, Li S, Ren S et al: Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. Lung Cancer, 2013; 81: 162–66

© Med Sci Monit, 2016; 22: 276-283
23. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 1995; 311: 899–909
24. Carbone DP, Ding K, Roder H et al: Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. J Thorac Oncol, 2012; 7: 1653–60
25. Zhou S, Ren S, Yan L et al: Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respiroligy, 2009; 14: 709–15
26. Thacheter N, Chang A, Parikh P et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005; 366: 1527–37
27. Bronte G, Rizzo S, La Paglia L et al: Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev, 2010; 36(Suppl.3): S21–29
28. Zhu CQ, da Cunha Santos G, Ding K et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol, 2008; 26: 4268–75
29. Sone T, Kasahara K, Kimura H et al: Epidermal growth factor receptor mutations and gene amplification in nonsmall cell lung cancer: molecular analysis of IDEAL/INTACT gefitinib trials. J Clin Oncol, 2005; 23: 8081–92
30. Eberhard DA, Johnson BE, Amler LC et al: Mutations in the epidermal growth factor receptor and KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 2005; 23: 5900–9
31. Mak RH, Doran E, Muzikansky A et al: Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist, 2011; 16: 886–95
32. Goto K, Ichinose Y, Ohe Y et al: Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol, 2012; 7: 115–21
33. Pérez-Soler R, Chachoua A, Hammond LA et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 2004; 22: 3238–47
34. Sridhar SS, Seymour L, Shepherd FA: Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol, 2003; 4: 397–406
35. Fukuoka M, Yano S, Giaccone G et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL Trial). J Clin Oncol, 2003; 21: 2237–46. [Erratum: J Clin Oncol, 2004; 22: 4811]
36. Kris MG, Natalie RB, Herbst RS et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 2003; 290: 2149–58
37. Pérez-Soler R, Chachoua A, Hammond LA et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 2004; 22: 3238–47
38. Massarelli E, Andre F, Liu DD et al: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer, 2003; 39: 55–61
39. Bai H, Wang Z, Chen K et al: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol, 2012; 30: 3077–83